Alteplase Trial Puts ENCHANTED Asian Sites On The Map
This article was originally published in PharmAsia News
Executive Summary
As well as establishing the benefits of lower dosing, new results from a multinational clinical trial with clot-buster alteplase have highlighted the strong performance of Asian study sites, breaking some perceptions in the process.
You may also be interested in...
What Makes Asia Appealing For Clinical Trials?
Asia is continuing to emerge as a global hot spot for clinical trials, helped by positive factors including patient availability and competitive costs, but challenges remain, a recent conference in Seoul heard.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.